# RELEVENT (NCT03921671)

> Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03921671
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Claudia Proto
- Conditions: Thymic Carcinoma; Thymoma
- Interventions: Ramucirumab
- Enrollment: 60
- Primary outcome: Best tumour response (CR+PR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 20

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=relevent-nct03921671

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03921671", "email": "<work email>"}; the inbox owner confirms by the emailed link.